Navigation Links
Generic Products Compete With GlaxoSmithKline

Stiff competition offered by generic drug makers may well eat into the profit figures of GlaxoSmithKline, according to company sources. The Cox-2 painkiller of the organization is also likely to suffer as a result of this.// The company is also embroiled in a tax related dispute with the Government in the US. The sales of the company for the year rose by13% at £21.6 billion, while its earnings were at £6.7 billion.

The sales of Advair, an asthma drug rose to £851 million during the 2005 last quarter, in spite of the US Food and Drug Administration (FDA) expressing strong reservations with regard to the drug. The sales figure for Avandia was at £289 million for the same quarter, while Avandamet crossed the £46 million figure.

The management chose to be cautious with regard to the 2006 earnings as a result of low priced generic competitors for the antidepressant Wellbutrin XL, hay fever medication Flonase, and Zofran. The per share earnings for 2006 is forecast at only 10% by the company. The results of the Cox-2 painkiller’s phase-III tests are also not very encouraging, according to the management of GlaxoSmithKline. Further development with regard to the drug however is being undertaken.

As many as another seven medicines are expected to be launched in 2006, which are inclusive of Entereg, Arranon, and Avandaryl. The regulators will be called upon to give their approval for seven more medicines also, which is inclusive of an anti H5N1 bird flu vaccine. The organization is also seeking to make some acquisitions during the course of the year. The consumer healthcare business of Pfizer is reported to be one among the targets of the compay.
'"/>




Page: 1

Related medicine news :

1. Generic drug costs remain shackled
2. FDA Approves Indian Generic Drug For AIDS Treatment
3. Proper Validation of Generic Drugs Could Save Millions of AIDS Patients
4. AIDS Generic Drugs Approved by FDA for Sale in US
5. HIV Mortality declining in India due to Generic Antiretroviral therapy drugs
6. Generic Drugs Usage In US Can Save $20 Billion – Express Script Surve
7. ViroPharma Shares Fall As FDA Moves Towards Generic Vancocin
8. Ranbaxy Expands By Acquiring A Generic Company In Belgium
9. First Generic Version of Lexapro permitted by US
10. Dr Reddys Launches Generic Version Of Mercks Proscar Tablets
11. Ranbaxy Acquires Glaxosmithklines Generic Unit in Spain
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... , , , WHEN: ... , , , , LOCATION: , , , Online, with ... , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice ... Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... industry is witnessing an exceptional era. Several new demand spaces, such ...
Breaking Medicine Technology: